David Shook - Jun 9, 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Chief Medical Officer
Signature: /s/ Charles Newton, as Attorney-in-Fact
Stock symbol: LYEL
Transactions as of: Jun 9, 2025
Transactions value $: $0
Form type: 4
Date filed: 6/11/2025, 05:45 PM
Previous filing: Jan 17, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Shook David	Chief Medical Officer	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO	/s/ Charles Newton, as Attorney-in-Fact	2025-06-11	0001959742

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Award	$0	+21.9K		$0.00	21.9K	Jun 9, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Option (right to buy)	Award	$0	+43.8K		$0.00	43.8K	Jun 9, 2025	Common Stock	43.8K	$12.47	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan ("RSUs"). 25% of the total shares subject to the RSUs will vest on June 9, 2026, and an additional 1/16th of the total shares subject to the RSUs per quarter thereafter, subject to the reporting person providing service through the applicable vesting date.
F2	25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date.